Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$27,000.00
Evaluating the Cardioprotective Potential of Apolipoprotein A1 in Doxorubicin Therapy
FY 2024-25
Summary
Cancer is the leading cause of death in Canada, with 2 in 5 Canadians expected to develop cancer and 1 in 4 likely to die from it. Chemotherapy drugs like doxorubicin (DOX) have significantly improved survival rates, but they can also cause serious heart damage, leading to heart failure and making recovery difficult for patients. Although some drugs aim to reduce this damage, they often compromise the effectiveness of cancer treatment or cause other unwanted side effects.Recent studies suggest that apolipoprotein A1 (ApoA1), a protein naturally found in the body, may protect against heart damage caused by DOX. ApoA1 has also been shown to slow the growth of cancer cells, making it a promising candidate for further investigation. This research will test whether ApoA1 can both protect the heart and enhance cancer treatment effectiveness. Using a mouse model, the study will explore whether adding ApoA1 to chemotherapy can prevent heart damage without compromising the cancer-fighting capabilities of DOX.If successful, this research could lead to safer chemotherapy treatments that protect the heart while still effectively treating cancer. It may improve the quality of life for cancer patients and survivors by reducing long-term heart damage and offering more effective, safer treatment options.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530176
Name
Zhang Chi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the Cardioprotective Potential of Apolipoprotein A1 in Doxorubicin Therapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apolipoprotein A1; Cancer; Chemotherapy; Doxorubicin
Abstract
Cancer is the leading cause of death in Canada, with 2 in 5 Canadians expected to develop cancer and 1 in 4 likely to die from it. Chemotherapy drugs like doxorubicin (DOX) have significantly improved survival rates, but they can also cause serious heart damage, leading to heart failure and making recovery difficult for patients. Although some drugs aim to reduce this damage, they often compromise the effectiveness of cancer treatment or cause other unwanted side effects.Recent studies suggest that apolipoprotein A1 (ApoA1), a protein naturally found in the body, may protect against heart damage caused by DOX. ApoA1 has also been shown to slow the growth of cancer cells, making it a promising candidate for further investigation. This research will test whether ApoA1 can both protect the heart and enhance cancer treatment effectiveness. Using a mouse model, the study will explore whether adding ApoA1 to chemotherapy can prevent heart damage without compromising the cancer-fighting capabilities of DOX.If successful, this research could lead to safer chemotherapy treatments that protect the heart while still effectively treating cancer. It may improve the quality of life for cancer patients and survivors by reducing long-term heart damage and offering more effective, safer treatment options.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, Chi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~